Parkwood LLC Aerovate Therapeutics, Inc. Transaction History

Parkwood LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$1.41 - $30.75 $1,041 - $22,724	739 Added 4.17%	18,467 $31,000
Q1 2024 May 15, 2024	BUY	$17.68 - $29.57 $34,334 - $57,424	1,942 Added 12.3%	17,728 $524,000
Q4 2023 Feb 14, 2024	SELL	$9.58 - $24.25 $46,625 - $118,024	-4,867 Reduced 23.57%	15,786 $357,000
Q3 2023 Nov 14, 2023	SELL	$12.9 - $18.88 $28,109 - $41,139	-2,179 Reduced 9.54%	20,653 $280,000
Q2 2023 Aug 14, 2023	SELL	$15.63 - $22.01 $47,374 - $66,712	-3,031 Reduced 11.72%	22,832 $392,000
Q1 2023 May 15, 2023	BUY	$19.17 - $27.7 $101,658 - $146,893	5,303 Added 25.79%	25,863 $522,000
Q4 2022 Feb 14, 2023	SELL	$15.92 - $30.52 $12,481 - $23,927	-784 Reduced 3.67%	20,560 $602,000
Q3 2022 Nov 14, 2022	SELL	$14.77 - $25.79 $163,503 - $285,495	-11,070 Reduced 34.15%	21,344 $354,000
Q2 2022 Aug 15, 2022	BUY	$10.8 - $16.91 $350,071 - $548,120	32,414 New	32,414 $32,000
Q1 2022 May 13, 2022	SELL	$8.25 - $18.33 $306,537 - $681,069	-37,156 Closed	0 $0
Q4 2021 Feb 11, 2022	SELL	$9.14 - $21.54 $99,653 - $234,850	-10,903 Reduced 22.69%	37,156 $438,000
Q3 2021 Nov 12, 2021	BUY	$11.76 - $22.49 $565,173 - $1.08 Million	48,059 New	48,059 $1.01 Million

28.1M

116K

26.6K

Ticker AVTE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 24,448,100
Market Cap $61.9M
Description
Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which ...

Get notified when there are updates to the investment portfolio of Parkwood LLC, based on Form 13F filings with the SEC.

Stay updated on Parkwood LLC with notifications on news.